Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 1.36
(3.82%)
SEK 1.36
(3.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 62.15 Million SEK | -32.16% |
| 2022 | 91.61 Million SEK | -24.2% |
| 2021 | 120.86 Million SEK | 165.63% |
| 2020 | 45.5 Million SEK | -48.31% |
| 2019 | 88.02 Million SEK | 30.59% |
| 2018 | 67.4 Million SEK | -35.99% |
| 2017 | 105.3 Million SEK | 275.06% |
| 2016 | 28.07 Million SEK | 13.63% |
| 2015 | 24.71 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 62.15 Million SEK | -32.16% |
| 2023 Q1 | 65.76 Million SEK | -28.22% |
| 2023 Q2 | 65.76 Million SEK | 0.0% |
| 2023 Q4 | 62.15 Million SEK | 0.0% |
| 2023 Q3 | 62.15 Million SEK | -5.49% |
| 2022 Q3 | 91.61 Million SEK | -9.18% |
| 2022 Q1 | 100.87 Million SEK | -16.54% |
| 2022 Q2 | 100.87 Million SEK | 0.0% |
| 2022 FY | 91.61 Million SEK | -24.2% |
| 2022 Q4 | 91.61 Million SEK | 0.0% |
| 2021 FY | 120.86 Million SEK | 165.63% |
| 2021 Q1 | 56.91 Million SEK | 25.09% |
| 2021 Q4 | 120.86 Million SEK | 0.0% |
| 2021 Q3 | 120.86 Million SEK | 112.35% |
| 2021 Q2 | 56.91 Million SEK | 0.0% |
| 2020 Q4 | 45.5 Million SEK | 0.0% |
| 2020 Q2 | 68.83 Million SEK | -11.78% |
| 2020 Q3 | 45.5 Million SEK | -33.9% |
| 2020 Q1 | 78.02 Million SEK | -11.36% |
| 2020 FY | 45.5 Million SEK | -48.31% |
| 2019 Q4 | 88.02 Million SEK | -11.46% |
| 2019 Q2 | 117.16 Million SEK | 104.89% |
| 2019 FY | 88.02 Million SEK | 30.59% |
| 2019 Q1 | 57.18 Million SEK | -15.16% |
| 2019 Q3 | 99.41 Million SEK | -15.15% |
| 2018 Q4 | 67.4 Million SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 FY | 67.4 Million SEK | -35.99% |
| 2018 Q2 | 87.78 Million SEK | 0.0% |
| 2017 Q4 | 105.3 Million SEK | 152.54% |
| 2017 FY | 105.3 Million SEK | 275.06% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | 41.69 Million SEK | 0.0% |
| 2016 FY | 28.07 Million SEK | 13.63% |
| 2016 Q4 | 28.07 Million SEK | 0.0% |
| 2015 FY | 24.71 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| 2cureX AB (publ) | 16.62 Million SEK | -273.847% |
| Abliva AB (publ) | 87.49 Million SEK | 28.968% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 28.62% |
| AcouSort AB (publ) | 34.51 Million SEK | -80.083% |
| Active Biotech AB (publ) | 44 Million SEK | -41.255% |
| Alzinova AB (publ) | 123.18 Million SEK | 49.547% |
| Amniotics AB (publ) | 26.08 Million SEK | -138.258% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -132.231% |
| Aptahem AB (publ) | 63.02 Million SEK | 1.385% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -922.741% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 47.529% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 95.561% |
| BioArctic AB (publ) | 1.18 Billion SEK | 94.76% |
| Biosergen AB | 7.2 Million SEK | -763.102% |
| Biovica International AB (publ) | 131.4 Million SEK | 52.703% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 96.73% |
| Camurus AB (publ) | 1.9 Billion SEK | 96.742% |
| Cantargia AB (publ) | 223.71 Million SEK | 72.218% |
| Corline Biomedical AB | 100.1 Million SEK | 37.913% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -317.997% |
| CombiGene AB (publ) | 120.61 Million SEK | 48.469% |
| Cyxone AB (publ) | 43.65 Million SEK | -42.371% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -118.016% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 71.364% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 91.824% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -105.985% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 21.019% |
| Fluicell AB (publ) | 9.34 Million SEK | -565.439% |
| Genovis AB (publ.) | 288.85 Million SEK | 78.483% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 27.075% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 93.895% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 82.31% |
| Mendus AB (publ) | 755.95 Million SEK | 91.778% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 64.91% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 55.794% |
| I-Tech AB | 152.44 Million SEK | 59.229% |
| Intervacc AB (publ) | 259.61 Million SEK | 76.06% |
| Kancera AB (publ) | 65.64 Million SEK | 5.318% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 95.061% |
| LIDDS AB (publ) | 17.65 Million SEK | -252.036% |
| Lipum AB (publ) | 12.11 Million SEK | -413.229% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -84.965% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 77.703% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -210.124% |
| Nanologica AB (publ) | 77.42 Million SEK | 19.73% |
| NextCell Pharma AB | 81.28 Million SEK | 23.541% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 73.927% |
| OncoZenge AB (publ) | 20.34 Million SEK | -205.565% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -635.092% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -48.126% |
| Saniona AB (publ) | 64.14 Million SEK | 3.104% |
| Simris Alg AB (publ) | 174.55 Million SEK | 64.393% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -17.301% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 0.361% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -186.377% |
| SynAct Pharma AB | 228.01 Million SEK | 72.743% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 87.476% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 90.489% |
| Xintela AB (publ) | 18.39 Million SEK | -237.874% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 91.878% |
| Ziccum AB (publ) | 14.97 Million SEK | -315.122% |